Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide Press release: ir.lisata.com/news-releases/…

$LSTA Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal tinyurl.com/2brvlmjx @lisata_tx $8NE #LSTA #8NE

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer Read full press release: ir.lisata.com/news-releases/…

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Read more: ir.lisata.com/news-releases/… #LisataTherapeutics

Join us today for our 3Q 2025 Financial Results Conference Call at 4:30pm ET. To join, please refer to the dial-in info below: Participant Toll-Free dial: (800) 715-9871 Participant Toll/Int'l dial: (646) 307-1963 Conference ID: 6375221 Webcast: edge.media-server.com/mmc/p/d7yefkch/

Lisata Therapeutics is proud to announce we have been named ‘Overall BioPharma Solution of the Year’ in the 5th Annual BioTech Breakthrough Awards program conducted by @TopTechAwards. Read more: ir.lisata.com/news-releases/… #BioTechBreakthrough #BioPharma #LisataTherapeutics

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent. Read press release: ir.lisata.com/news-releases/… #LisataTherapeutics $LSTA

On November 6, we will announce our Q3 2025 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET. To participate on the call: Participant Toll-Free dial: (800) 715-9871 Participant Toll/Int'l dial: (646) 307-1963 Conference ID: 6375221

#ICYMI: Preliminary CENDIFOX data was presented at @AACR last month, showing certepetide + FOLFIRINOX was safe & feasible in pancreatic cancer patients with encouraging efficacy signals. Read more: bit.ly/4o9XGF5 #LisataTherapeutics

Our CENDIFOX data featured in @CancerNetwork, highlighting encouraging preliminary results with certepetide + FOLFIRINOX in pancreatic cancer patients. Read the coverage: cancernetwork.com/view/certepeti… #LisataTherapeutics #PancreaticCancer

The CendR Platform® addresses a critical challenge: dense tumor barriers that prevent drugs from reaching cancer cells. Certepetide activates a novel uptake pathway for enhanced, selective drug delivery to solid tumors. Learn more: bit.ly/45ZuJFB #LisataTherapeutics

Proud to announce that our CendR Platform® is a finalist for the Fierce Innovation Awards: Life Sciences Edition in the Drug Delivery Technology category. Winners announced Nov 19th. #FierceLifeSciencesAwards #FierceInnovationAwards @LifeSciEvents

Lisata Therapeutics to Present at LD Micro Main Event XIX Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

Catalent and @lisata_tx have entered a global license agreement to develop next-gen ADCs using our SMARTag® platform and Lisata’s certepetide product candidate—advancing targeted cancer therapies. Read the full press release: ow.ly/yVrg50X8FwF #ADCs #SMARTag #Biologics

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

Today we recognize #WorldCancerResearchDay and the critical role of research in improving cancer treatment. At Lisata, our CendR Platform® and certepetide aim to enhance drug delivery to solid tumors, contributing to better patient outcomes. #CancerResearch

Today our CEO David J. Mazzo, PhD joined the FDA CEO Forums in Raleigh, calling for a public-private working group to maximize AI benefits in drug development while maintaining FDA's high safety & efficacy standards. Collaboration drives innovation. #FDA #AI #Innovation

#ICYMI: Our certepetide population pharmacokinetic study was published in @ACCP1_org journal in January. The analysis provides insights to inform dose optimization in ongoing trials. Read more: bit.ly/45GDoLN #LisataTherapeutics

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

Certepetide’s unique mechanism: 1) Targets tumor-specific integrins 2) Creates CendR fragment binding to neuropilin-1 3) Activates uptake pathway 4) Enhances drug penetration in tumors while sparing healthy tissue. Learn more: youtube.com/watch?v=dd-Sga… #CancerResearch